Ravindranath Patel
Impact in
- Oncology top 2%
- Cancer-related Molecular Pathways
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
-
- Advanced Breast Cancer Therapies
Papers in
-
- Advanced Breast Cancer Therapies 8
- Oncology 9
- Cancer Treatment and Pharmacology 4
- HER2/EGFR in Cancer Research 4
- Cancer-related Molecular Pathways 2
- Co-authors
- Dennis J. Slamon (6 shared papers)Tamás Pintér (6 shared papers)Johannes Ettl (5 shared papers)Xin Huang (5 shared papers)Marcus Schmidt (6 shared papers)Katalin Boér (6 shared papers)Richard S. Finn (5 shared papers)Igor Bondarenko (5 shared papers)
- Journals
- Journal of Clinical Oncology (7 papers)Cancer Research (2 papers)Blood (2 papers)Breast Cancer Research (1 paper)The Lancet Oncology (1 paper)
- Partner nations
- United StatesGermanyHungary
In The Last Decade
Ravindranath Patel
15 papers receiving 1.8k citations
Hit Papers
Peers
Comparison fields: 5 of 66
- Oncology 1.4k
- Pulmonary and Respiratory Medicine 1.5k
- Cancer Research 596
- Genetics 365
- Genetics 131
Countries citing papers authored by Ravindranath Patel
This map shows the geographic impact of Ravindranath Patel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ravindranath Patel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ravindranath Patel more than expected).
Fields of papers citing papers by Ravindranath Patel
This network shows the impact of papers produced by Ravindranath Patel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ravindranath Patel. The network helps show where Ravindranath Patel may publish in the future.
Co-authors
The 25 scholars most cited alongside Ravindranath Patel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Hit paper breakdown → | 2014 | 1412 |
| 2 | 2016 | 136 | |
| 3 | 2020 | 111 | |
| 4 | 2017 | 53 | |
| 5 | 2019 | 38 | |
| 6 | 2014 | 37 | |
| 7 | 2017 | 16 | |
| 8 | 2014 | 5 | |
| 9 | 2011 | 3 | |
| 10 | A phase 2, randomized, open-label study of lucitanib in patients with FGF aberrant metastatic breast cancer. | 2015 | 2 |
| 11 | 2009 | 2 | |
| 12 | 2019 | 1 | |
| 13 | 2018 | 1 | |
| 14 | 2019 | 1 | |
| 15 | 2018 | 1 |
About Ravindranath Patel
Ravindranath Patel is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology and Hematology, having authored 15 papers that have together received 1.8k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (8 papers), Cancer Treatment and Pharmacology (4 papers), Breast Cancer Treatment Studies (4 papers), HER2/EGFR in Cancer Research (4 papers), Multiple Myeloma Research and Treatments (3 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers), Cancer-related Molecular Pathways (2 papers) and Chronic Myeloid Leukemia Treatments (2 papers). The work is most often cited by research in Oncology (1.4k citations), Pulmonary and Respiratory Medicine (1.5k citations), Cancer Research (596 citations), Genetics (365 citations) and Genetics (131 citations). Ravindranath Patel has collaborated with scholars based in United States, Germany and Hungary. Frequent co-authors include Dennis J. Slamon, Tamás Pintér, Johannes Ettl, Xin Huang, Marcus Schmidt, Katalin Boér, Richard S. Finn, Igor Bondarenko, John Crown and Anu Thummala. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Blood, Breast Cancer Research and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.